The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 132, Issue 3, 2014, Pages 560-565

  Fader, Amanda Nickles ^a   Java, James ^b   Krivak, Thomas C ^c   Bristow, Robert E ^d   Tergas, Ana I ^a   Bookman, Michael A ^e   Armstrong, Deborah K ^a   Tanner, Edward J ^a   Gershenson, David M ^f  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

CA 125; Low grade serous carcinoma; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

CA-125; LOW GRADE SEROUS CARCINOMA; OVARIAN CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 84896390476     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.016     Document Type: Article

References (31)

1. R.C. Bast Jr., M. Feeney, H. Lazarus, L.M. Nadler, R.B. Colvin, and R.C. Knapp Reactivity of a monoclonal antibody with human ovarian carcinoma J Clin Invest 68 1981 1331 1337
2. B.W. Yin, and K.O. Lloyd Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16 J Biol Chem 20 2001 27371 27375
3. R.C. Bast Jr., T.L. Klug, E. St. John, E. Jenison, J.M. Niloff, and H. Lazarus et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883 887
4. I. Jacobs, and R.C. Bast Jr. The CA 125 tumour-associated antigen: a review of the literature Hum Reprod 4 1989 1 12
5. K.K. Zorn, C. Tian, W.P. McGuire, W.J. Hoskins, M. Markman, and F.M. Muggia et al. Prognostic value of pretreatment CA-125 in advanced ovarian carcinoma: a Gynecologic Oncology Group study Cancer 115 2009 1028 1035
6. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
7. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clarke-Pearson, and L.F. Carson et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007
8. F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, and S.L. Lentz et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 18 2000 106 115
9. P.G. Rose, S. Nerenstone, M.F. Brady, D. Clarke-Pearson, G. Olt, and S.C. Rubin et al. Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2497
10. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
11. D. Spriggs, M.F. Brady, S.C. Rubin, M. Hanley, L.J. Copeland, and D. Clarke-Pearson et al. A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer Proc ASCO 2004 449 (23(abstr #5004))
12. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
13. A. Malpica, M.T. Deavers, D.C. Bodurka, E.N. Atkinson, D.M. Gershenson, and E.G. Silva Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
14. D.C. Bodurka, M.T. Deavers, C. Tian, C.C. Sun, A. Malpica, and R.L. Coleman Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study Cancer 118 2012 3087 3094
15. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, and M. Friedlander et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup J Clin Oncol 27 2009 1419 1425
16. K. Pearson On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling Phil Mag Series 5 1900 157 175
17. H.B. Mann, and D.R. Whitney On a test of whether one of two random variables is stochastically larger than the other Ann Math Stat 18 1947 50 60
18. W.H. Kruskal, and W.A. Wallis Use of ranks in one-criterion variance analysis J Am Stat Assoc 47 1952 583 621
19. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
20. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
21. D.R. Cox Regression models and life-tables J R Stat Soc Ser B (Stat Methodol) 34 1972 187 220
22. R Development Core Team R: a language and environment for statistical computing 2012 R Foundation for Statistical Computing Vienna, Austria (http://www.R-project.org/, 3-900051-07-0)
23. P.M. Fayers, G. Rustin, M. Wood, A. Nelstrop, R.C. Leonard, and P. Wilkinson et al. The prognostic value of serum CA125 in patients with advanced ovarian cancer: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer Int J Gynaecol Oncol 3 1993 286 292
24. T. Meyer, and G.J. Rustin Role of tumor markers in monitoring epithelial ovarian cancer Br J Cancer 82 2000 1535 1538
25. A.N. Fader, J. Java, S.M. Ueda, M. Bookman, R.E. Bristow, and D. Armstrong et al. Survival outcomes in women with low grade (grade 1) serous ovarian carcinoma: a Gynecologic Oncology Group study Obstet Gynecol 122 2, PART 1 2013 225 232
26. K.M. Schmeler, and D.M. Gershenson Low-grade serous ovarian cancer: a unique disease Curr Oncol Rep 10 2008 519 523
27. D.M. Gershenson, C.C. Sun, K.H. Lu, R.L. Coleman, Sood Ak, and A. Malpica et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary Obstet Gynecol 108 2006 361 368
28. N.L. Sieben, P. Macropoulos, G.M. Roemen, S.M. Kolkman-Uljee, G. Jan Fleuren, and R. Houmadi et al. In ovarian neoplasms, BRAF, but not KRAS, mutations and restricted to low-grade serous tumours J Pathol 202 2004 336 340
29. G. Singer, R. Oldt III, Y. Cohen, B.G. Wang, D. Sidransky, and R.J. Kurman et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
30. J. Farley, W.E. Brady, V. Vathipadiekal, H.A. Lankes, R. Coleman, and M.A. Morgan et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol 14 2013 134 140
31. R.W. Talbot, D.J. Jacobsen, D.M. Nagorney, G.D. Malkasian, and R.E. Ritts Jr. Temporary elevation after abdominal surgical treatment for benign disease and cancer Surg Gynecol Obstet 168 1989 407 412